Stockreport

Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference

Cellectar Biosciences, Inc.  (CLRB) 
Last cellectar biosciences, inc. earnings: 11/12 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.cellectar.com
PDF 50% overall response rate in cohort of patients receiving fractionated 37.5 mCi/m2 dose of CLR 131 31.3% overall response rate in multiple myeloma patients over all dose [Read more]